JTO Clinical and Research Reports (Feb 2022)

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

  • Mizuha Haraguchi Hashiguchi, MD, PhD,
  • Takashi Sato, MD, PhD,
  • Hiroki Yamamoto, MD,
  • Rinako Watanabe, MD,
  • Junko Kagyo, MD,
  • Hideharu Domoto, MD, PhD,
  • Tetsuya Shiomi, MD, PhD

Journal volume & issue
Vol. 3, no. 2
p. 100271

Abstract

Read online

MET tyrosine kinase inhibitors, capmatinib and tepotinib, have been recently introduced for the treatment of advanced NSCLC with MET exon 14 skipping mutations. Although interstitial lung disease (ILD) induced by these drugs is reported, its optimal management and whether they can be rechallenged remain unclear. We report the first successful case of tepotinib treatment after capmatinib-induced ILD. Switching MET tyrosine kinase inhibitors after drug-induced ILD could be a clinical option, which warrants further investigation.

Keywords